bioMerieux, Inc.   
Esther Hernandez   
Regulatory Affairs Specialist 595 Anglum Road   
Hazelwood, Missouri 63042

Re: K213899 Trade/Device Name: VITEK 2 AST-Yeast Caspofungin $( \leq 0 . 1 2 5 - \geq 8 \mu \mathrm { g / m L } )$ ), VITEK 2 AST-YS Caspofungin $( \leq 0 . 1 2 5 - \geq 8 \mu \mathrm { g / m L } )$ ), VITEK 2 AST-YS Caspofungin Regulation Number: 21 CFR 866.1645 Regulation Name: Fully automated short-term incubation cycle antimicrobial susceptibility system Regulatory Class: Class II Product Code: LON, LTT, LTW

Dear Esther Hernandez:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated July 12, 2022. Specifically, FDA is updating this SE Letter to provide the correct Indications for Use form (FORM FDA 3881) as an administrative correction.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Ribhi Shawar, Ph.D., OHT7: Office of In Vitro Diagnostics, 301-796-6698, Ribhi.Shawar@fda.hhs.gov.

Sincerely,

# Natasha Griffin -S

Ribhi Shawar, Ph.D.   
Branch Chief   
Division of Microbiology Devices   
OHT7: Office of In Vitro Diagnostics   
Office of Product Evaluation and Quality Center for Devices and Radiological Health bioMerieux, Inc.   
Esther Hernandez   
Regulatory Affairs Specialist 595 Anglum Road   
Hazelwood, Missouri 63042

Re: K213899 Trade/Device Name: VITEK 2 AST-Yeast Caspofungin $( \leq 0 . 1 2 5 - \geq 8 \mu \mathrm { g / m L } )$ ), VITEK 2 AST-YS Caspofungin $( \leq 0 . 1 2 5 - \geq 8 \mu \mathrm { g / m L } )$ ), VITEK 2 AST-YS Caspofungin Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System Regulatory Class: Class II Product Code: LON, LTT, LTW Dated: December 13, 2021 Received: December 14, 2021

Dear Esther Hernandez:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531- 542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Natasha Griffin -S

Ribhi Shawar, Ph.D. (ABMM)   
Branch Chief   
General Bacteriology and Antimicrobial Susceptibility Branch   
Division of Microbiology Devices   
OHT7: Office of In Vitro Diagnostics   
Office of Product Evaluation and Quality   
Center for Devices and Radiological Health

Enclosure

<table><tr><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.</td></tr><tr><td>510(k) Number (if known) K213899</td><td></td></tr></table>

Device Name

VITEK¬Æ 2 AST-Yeast Caspofungin $( \leq 0 . 1 2 5 ~ - \geq 8 ~ \mu \mathrm { g / m L } )$

Indications for Use (Describe)

VITEK¬Æ 2 AST-Yeast Caspofungin is designed for antifungal susceptibility testing of Candida species and is intended for use with the VITEK¬Æ 2 and VITEK¬Æ 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antifungal agents. ${ \mathrm { V I T E K } } ^ { \circledast } 2$ AST-Yeast Caspofungin is a quantitative test.

Caspofungin has been shown to be active against most strains of the microorganisms listed below, according to he FDA label for this antifungal.

Active in vitro and in clinical infections:   
Candida albicans   
Candida guillermondii   
Candida krusei   
Candida parapsilosis   
Candida tropicalis

The VITEK¬Æ 2 Fungal Susceptibility Card is intended for use with the VITEK¬Æ 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant yeasts to antifungal agents when used as instructed.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

‚ÄúAn agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.‚Äù

# 510(k) SUMMARY

# VITEK¬Æ 2 AST-YS Caspofungin

A. 510(k) Submission Information:

Submitter‚Äôs Name:

Address:

Contact Person:

bioM√©rieux, Inc.   
595 Anglum Road   
Hazelwood, MO 63042   
Esther Hernandez   
Regulatory Affairs Specialist 314 -731-8841   
314-731-8689   
December 8, 2021

Phone Number: Fax Number: Date of Preparation:

# B. Device Name:

Formal/Trade Name:

VITEK¬Æ 2 AST-Yeast Caspofungin $( \leq 0 . 1 2 5 - \geq 8 $ $\mu \mathrm { g } / \mathrm { m L } )$

Classification Name:

21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System Product Code LON/77/7:

Common Name:

VITEK¬Æ 2 AST-YS Caspofungin

# C. Predicate Device:

VITEK¬Æ 2 AST-Yeast Caspofungin (K151817)

# D. Device Description:

The principle of the $\mathrm { V I T E K } ^ { \textregistered } 2$ AST cards is based on the microdilution minimum inhibitory concentration (MIC) technique reported by MacLowry and Marsh(1) and Gerlach(2). The VITEK¬Æ 2 AST card is essentially a miniaturized, abbreviated and automated version of the doubling dilution technique (3).

Each VITEK $^ { \textregistered } 2$ AST card contains 64 wells. A control well which only contains microbiological culture media is resident on all cards. The remaining wells contain premeasured portions of a specific antibiotic combined with culture media. The bacterial or yeast isolate to be tested is diluted to a standardized concentration with $0 . 4 5 - 0 . 5 \%$ saline before being used to rehydrate the

antimicrobial medium within the card. The VITEK $^ { \textregistered } 2$ System automatically fills, seals and places the card into the incubator/reader. The VITEK $^ { \textregistered } 2$ Compact has a manual filling, sealing and loading operation. The VITEK¬Æ 2 Systems monitor the growth of each well in the card over a defined period of time. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.

VITEK¬Æ 2 AST-YS Caspofungin has the following concentrations in the card: 0.125, 0.5, 2, and 8 (equivalent standard method concentration by efficacy in $\mu \mathrm { g / m L }$ ).

# E. Substantial Equivalence Information

The similarities and differences of the VITEK 2 AST-YS Caspofungin when compared to the predicate device, VITEK 2 AST-YS Caspofungin (K151817), are described in the following table. The only difference between both devices are the Indications for Use and the breakpoints used to analyze the data performance. The below table provides the similarities and differences:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="3" rowspan="1">Device:VITEK¬Æ 2 AST-YS Caspofungin</td><td colspan="1" rowspan="1">Predicate:VITEK¬Æ 2 AST-YS Caspofungin(K151817)</td></tr><tr><td colspan="5" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="2">Intended Use</td><td colspan="3" rowspan="1">VITEK ¬Æ 2 AST-Yeast Caspofunginis designed for antifungalsusceptibility testing of Candidaspecies and is intended for use withthe VITEK ¬Æ 2 and VITEK ¬Æ 2Compact Systems as a laboratory aidin the determination of in vitrosusceptibility to antifungal agents.VITEK ¬Æ 2 AST-Yeast Caspofunginis a quantitative test. Caspofunginhas been shown to be active againstmost strains of the microorganismslisted below, according to the FDAlabel for this antifungal.Active in vitro and in clinical</td><td colspan="1" rowspan="2">VITEK ¬Æ 2 AST-Yeast Caspofungin isdesigned for antifungal susceptibilitytesting of Candida species and isintended for use with the VITEK ¬Æ 2and VITEK¬Æ 2 Compact Systems as alaboratory aid in the determination ofin vitro susceptibility to antifungalagents. VITEK¬Æ 2 AST-YeastCaspofungin is a quantitative test.Caspofungin has been shown to beactive against most strains of themicroorganisms listed below,according to the FDA label for thisantifungal.Active in vitro and in clinicalinfections:Candida albicansCandida glabrataCandida guilliermondiiCandida kruseiCandida parapsilosisCandida tropicalisThe VITEK ¬Æ 2 Antimicrobial</td></tr><tr><td colspan="3" rowspan="1">infections:Candida albicansCandida guilliermondiiCandida kruseiCandida parapsilosisCandida tropicalisThe VITEK ¬Æ 2 Fungal SusceptibilityCard is intended for use with the</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">b</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">VITEK ¬Æ 2 Systems in clinicallaboratories as an in vitro test todetermine the susceptibility ofclinically significant yeasts toantifungal agents when used asinstructed.</td><td colspan="1" rowspan="1">Susceptibility Test (AST) is intended tofor use with the VITEK 2 Systems forthe automated quantitative or qualitativesusceptibility testing of isolated coloniesfor most clinically significant aerobicGram-negative bacilli, Staphylococcusspp., Enterococcus spp., Streptococcusspp. and clinical significant yeast.</td></tr><tr><td colspan="1" rowspan="1">Test Methodology</td><td colspan="1" rowspan="1">Automated quantitative antimicrobialsusceptibility test for use with theVITEK ¬Æ 2 and VITEK ¬Æ 2 CompactSystems to determine the in vitrosusceptibility of yeast.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antimicrobial Agent</td><td colspan="1" rowspan="1">Caspofungin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Inoculum</td><td colspan="1" rowspan="1">Saline suspension of organism</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Card</td><td colspan="1" rowspan="1">VITEK ¬Æ 2 Yeast (AST) SusceptibilityTest Card</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analysis Algorithms</td><td colspan="1" rowspan="1">Discriminant Analysis</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">VITEK ¬Æ 2 and VITEK ¬Æ 2 CompactSystems</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Concentrations</td><td colspan="1" rowspan="1">0.125, 0.5, 2, 8</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Differences</td><td colspan="1" rowspan="1">canmaGllowb</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">Candida albicansCandida guilliermondiiCandida kruseiCandida parapsilosisCandida tropicalis</td><td colspan="1" rowspan="1">Candida albicansCandida glabrataCandida guilliermondiiCandida kruseiCandida parapsilosisCandida tropicalis</td></tr><tr><td colspan="1" rowspan="1">Breakpoints for Candidaspp.</td><td colspan="1" rowspan="1">Candida albicans: ‚â§0.25 (S), 0.5 (I),‚â•1 (R)Candida guilliermondii: ‚â§2 (S), 4(I), ‚â•8 (R)Candida krusei: ‚â§0.25 (S), 0.5 (I),‚â•1 (R)Candida parapsilosis: ‚â§2 (S), 4 (I),‚â•8 (R)Candida tropicalis: ‚â§0.25 (S), 0.5(I), ‚â•1 (R)</td><td colspan="1" rowspan="1">Candida spp.: ‚â§2 (S), - (I), - (R)</td></tr></table>

# F. Intended Use:

VITEK¬Æ 2 AST-Yeast Caspofungin is designed for antifungal susceptibility testing of Candida species and is intended for use with the ${ \mathrm { V I T E K } } ^ { \circledast } 2$ and ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antifungal agents. VITEK $^ { \textregistered } 2$ AST-Yeast Caspofungin is a quantitative test. Caspofungin has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antifungal.

Active in vitro and in clinical infections:   
Candida albicans   
Candida guilliermondii   
Candida krusei   
Candida parapsilosis   
Candida tropicalis

The VITEK¬Æ 2 Fungal Susceptibility Card is intended for use with the $\operatorname { V I T E K } ^ { \mathbb { B } } 2$ Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant yeasts to antifungal agents when used as instructed.

# G. Performance Overview:

VITEK $^ { \textregistered } 2$ AST-YS Caspofungin demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA (Issued August 28, 2009).

The Premarket Notification (Traditional 510[k]) presents data in support of VITEK¬Æ 2 AST-YS Caspofungin. An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of ${ \mathrm { V I T E K } } ^ { \mathbb { B } } 2$ AST-YS Caspofungin by comparing its performance with the CLSI broth microdilution reference method incubated at 24 hours (or up to 48 hours for isolates that show insufficient growth at 24 hours). The data is representative of performance on both the $\mathrm { V I T E K } ^ { \mathcal { \ B } } 2$ and VITEK $^ { \textregistered } 2$ Compact instrument platforms.

VITEK¬Æ 2 AST-YS Caspofungin demonstrated acceptable performance of $9 9 . 9 \%$ overall Essential Agreement and $9 7 . 5 \%$ overall Category Agreement with the reference method.   

<table><tr><td rowspan=3 colspan=1>Antimicrobial</td><td rowspan=3 colspan=1>Anti-microbialCode</td><td rowspan=3 colspan=1>AntibioticVersion</td><td rowspan=3 colspan=1>Bp1</td><td rowspan=3 colspan=1>Comment</td><td rowspan=1 colspan=4>Essential Agreement</td><td rowspan=1 colspan=4>Category Agreement</td><td rowspan=3 colspan=1>%Repro-ducibility</td></tr><tr><td rowspan=1 colspan=4>% Error</td><td rowspan=1 colspan=4>% Error</td></tr><tr><td rowspan=1 colspan=1>% EA</td><td rowspan=1 colspan=1>VME</td><td rowspan=1 colspan=1>ME</td><td rowspan=1 colspan=1>mE</td><td rowspan=1 colspan=1>% CA</td><td rowspan=1 colspan=1>VME</td><td rowspan=1 colspan=1>ME</td><td rowspan=1 colspan=1>mE</td></tr><tr><td rowspan=2 colspan=1>Caspofungin</td><td rowspan=2 colspan=1>CAS</td><td rowspan=2 colspan=1>cas02n</td><td rowspan=2 colspan=1>CLSI(FDA)</td><td rowspan=2 colspan=1>#, E,</td><td rowspan=1 colspan=1>(679/680)99.9</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>(663/680)97.5</td><td rowspan=1 colspan=1>(2/2)100.0</td><td rowspan=1 colspan=1>(0/663)0.0</td><td rowspan=1 colspan=1>(15/680)2.2</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=9>VIT 2 Caspofungin MIC values tended to bein exact agreement or at least one doubling dilution lower whentesting Candida albicans, Candida guilliermondii, Candida krusei, Candida parapsilosis, and Candidatropicals compared to the broth microdilution reference method. One very major error was observed or C.albicans and one very major error was observed for C. tropicalis using the VITEK 2 (both the automatic andmanal dilu methosEavey ma eror ws then reisan iola testean wa with slagreement with the reference method. One very major error was observed for C. tropicalis using the VITEK 2CT           the reference method</td></tr></table>

1 Abbreviations-Bp=breakpointcommittee;EA ${ . } =$ essentialagreement; $\mathrm { C A } =$ categoryagreement;VME $\mathbf { \Psi } =$ VeryMajor Error(susceptibleresultwithresistantreferenceresult);ME MajorError(resistant resultwithsusceptiblereference result); mE $=$ minor Error (susceptible or resistant result with an intermediate reference result, or an intermediate result with a susceptible or resistant reference result). $\# = \mathrm { U S }$ Food and Drug Administration 510(k) cleared CLSI $=$ Clinical and Laboratory Standards Institute

Reproducibility and Quality Control demonstrated acceptable results.

# H. Conclusion:

The performance data presented in this submission support a substantial equivalence decision. ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ AST-Yeast Caspofungin $( \leq 0 . 1 2 5 - \geq 8 ~ \mu \mathrm { g / m L } )$ ) is substantially equivalent to VITEK $^ { \textregistered } 2$ AST-Yeast Caspofungin (K151817).

# References:

1. MacLowry, J.D. and Marsh, H.H., Semi-automatic Microtechnique for Serial Dilution Antibiotic Sensitivity Testing in the Clinical laboratory, Journal of Laboratory Clinical Medicine, 72:685-687, 1968.   
2. Gerlach, E.H., Microdilution 1: A Comparative Study, p. 63-76. Current Techniques for Antibiotic Susceptibility Testing. A. Balows (ed.), Charles C. Thomas, Springfield, IL, 1974.   
3. Barry, A.L., The Antimicrobic Susceptibility Test, Principles and Practices, Lea and Febiger, Philadelphia, PA, 1976.